

ACUTE LIMB ISCHEMIA

Table of Contents

PERIPHERAL ARTERIAL DISEASE (PAD)	1
INTERMITTENT CLAUDICATION (IC)	1
CRITICAL LIMB ISCHEMIA (CLI).....	1
ACUTE LIMB ISCHEMIA (ALI).....	2
Risk Factors	2
Associated With Femoropopliteal and Type III Disease	3
The Most Severe Form of Peripheral Disease	3
PRIMARY CAUSES—THROMBOSIS OR EMBOLISM	3
THROMBOSIS.....	4
Most Common Sites of Thrombosis	4
Risk Factors for Thrombosis and Embolism	4
EMBOLISM	5
Most Common Sites of Embolism.....	5
Causes	5
BYPASS GRAFT OCCLUSIONS	5
POPLITEAL OR FEMORAL ARTERY ANEURYSM	5
CLINICAL CLASSIFICATIONS OF ACUTE LIMB ISCHEMIA	6
ISCHEMIC INJURY	7
CONSEQUENCES—MORTALITY AND LIMB LOSS	7
Mortality—Cause of Death.....	8
Amputation	8
Primary Amputation.....	8
Risk of Limb Loss Increases With Duration of Ischemia.....	8
SURVIVORS EXPERIENCE RAPID DETERIORATION	9
Two-Year Outcome	9
Exceptionally High Five-Year Mortality	10
SURVIVORS OF ALI, AMI AND STROKE COMPARED	10
30-Day Mortality Higher Than MI or Stroke	10
Morbidity and Mortality—ALI, AMI and Stroke.....	11
TREATMENT	12
Initial Therapy—Anticoagulation.....	12
Frail Elderly Patients with Serious Co-Morbidities.....	13
Amputation or Revascularization	13
Multiple Therapies Are The Norm	14
SURGERY	14
Thromboembolectomy	15
Bypass Grafts	15
Replacement Bypass Surgery	15
Thrombolysis	16
Outcome.....	16
Limb Salvage and Mortality	16

Complications	16
Reperfusion Injury	17
Compartment Syndrome	18
THROMBOLYSIS	18
Regional Lysis	18
Advantages.....	19
Disadvantages	19
Clinical Outcomes.....	20
Factors That Influence Amputation-Free Survival	20
Factors Associated With Higher Mortality	21
Complications	21
Contraindications	22
PLASMINOGEN ACTIVATORS.....	22
Streptokinase.....	22
Urokinase	23
Prourokinase	23
ThromboClear.....	23
Tissue Plasminogen Activators (t-PA).....	24
Activase.....	24
TNKase	24
Retavase	24
Fibrin Specificity	24
Limitations of Plasminogen Activators	25
Mechanism of Activity	25
Strategies to Overcome Limitations.....	26
PLASMINOGEN ACTIVATORS COMPARED	26
Difficult to Conclude That One Agent is Superior	26
Research is Sparse and Often Flawed.....	27
Similar Range of Bleeding Complications	27
Efficacy and Safety	27
Retavase—RELAX Trial	28
TNKase	29
THROMBOLYSIS AND SURGERY COMPARED	30
Three Prospective Randomized Trials	30
Meta-Analyses	31
THE ROLE OF GPIIb/IIIa INHIBITORS	32
Rationale for the Addition of Antiplatelet Agents.....	32
Benefit in the Coronary Setting	32
Potential Advantages in Acute Limb Ischemia.....	33
FDA-Approved GP IIb/IIIa Inhibitors	33
ReoPro.....	34
Peripheral Experience	34
Aggrastat.....	36
Peripheral Experience	36
Integrilin.....	37
Peripheral Experience	37

Comparison of GP IIb/IIIa Inhibitors	38
PLASMINOGEN ACTIVATORS IN RESEARCH	39
Staphylokinase	40
Desmoteplase	41
DIRECT FIBRINOLYTIC DRUGS.....	41
Plasmin.....	41
Microplasmin	42
Fibrolase.....	42
Alfimeprase.....	42
Clinical Trial Results in Acute Limb Ischemia.....	43
Phase III Trials in ALI	44
NEW PHARMACEUTICAL APPROACHES UNDER INVESTIGATION.....	44
TAFIa Inhibitors	45
Dual Activity Agents	45
Combined Antiplatelet and Anticoagulant Activity	45
Combined Fibrinolytic and Anticoagulant Activity	45
Proteomics.....	45
THROMBOLYTIC INFUSION CATHETERS	45
PERCUTANEOUS MECHANICAL THROMBECTOMY (PMT)	46
FDA-Approved Devices	46
Limitations	48
Complications	48
THROMBUS DISRUPTION DEVICES.....	49
Helix.....	49
THROMBUS ASPIRATION DEVICES.....	49
Pronto.....	50
Export Catheter	50
THROMBUS DISRUPTION AND ASPIRATION DEVICES	50
Maceration and Aspiration.....	50
X-Sizer Catheter System.....	50
Thrombex PMT System.....	50
Endovac.....	51
Rheolytic Thrombectomy	51
AngioJet System	51
Advantages.....	52
Efficacy	52
Adjunctive Procedures	53
Mortality and Amputation.....	53
Complications	54
Hydrolyser.....	54
Efficacy	54
Adjunctive Procedures	55
Mortality and Amputation.....	55
Complications	55
Oasis.....	55
Efficacy and Complications.....	55

ISOLATED THROMBOLYSIS	55
Bacchus Trellis.....	55
Efficacy	56
Adjunctive Procedures	56
Complications	57
ULTRASONIC THROMBECTOMY	57
Mechanism of Operation.....	57
Safety	58
Optimal Parameters.....	58
Frequency and Power.....	58
ENDOVASCULAR ULTRASOUND SYSTEMS.....	59
Resolution 360 System	59
Lysus Infusion System.....	60
Acolysis System.....	61
ULTRASOUND-MEDIATED MICROBUBBLE DESTRUCTION.....	61
Microbubbles For Thrombus	61
Targeted Drug and Gene Delivery	62
SonoLysis.....	62
In Acute Ischemic Stroke.....	63
Thrombosed Dialysis Grafts	64
Deep Vein Thrombosis	64
Acute Limb Ischemia.....	64
Other Commercial Microbubbles	64
Optison.....	64
Imagent/Imavist	65
Levovist.....	65
SonoVue.....	65
Albunex.....	66
Microbubbles in Late Clinical Trials for Myocardial Perfusion Assessment.....	66
OTHER NEW PERCUTANEOUS APPROACHES	66
CliRpath Excimer Laser.....	66
COMBINATION THERAPY	67
Debulking.....	67
Power Pulse Spray (PPS).....	67
Technique Description	67
Safety and Efficacy of Power Pulse Spray	68
SURGERY, THROMBOLYSIS, ANGIOJET AND PPS COMPARED.....	69
Outcomes	69
Cost	70
Thrombolysis	71
Surgery	72
Amputation	72
AngioJet	73
Power Pulse Spray (PPS).....	73
NUMBER OF PATIENTS PRESENTING WITH ALI.....	74
Incidence of Acute Limb Ischemia	74

Estimates Based on PAD Interventional Procedures	74
Estimates Based on Critical Limb Ischemia	75
National Hospital Discharge Survey Data	76
Estimated Number of ALI Procedures.....	76
Percentage of Bypass Operations Due to ALI	76
Percentage of Amputations Due to ALI.....	77
Percentage of ALI-Related Thrombolytic, Heparin and GP IIb/IIIa Infusions	77
Conclusions Regarding Number of ALI Patients	77
ESTIMATED NUMBER OF ACUTE LIMB ISCHEMIA PATIENTS	77
Based on Number of PAD Patients—2000 to 2020.....	77
Assumptions and Methods.....	78
Estimated Number of CLI and ALI Patients 2000-2020	78
ALI Patients Expected to Decline as a Percentage of CLI Patients.....	79
Factors That Could Mitigate The Decline	80
ALI MARKET ANALYSIS METHODOLOGY	81
ALI MARKET ESTIMATES IN NUMBER OF PROCEDURES 2000-2020	81
Number of Primary Procedures per Patient	81
Number of Patients Needing Revision Therapy	82
Data on ALI Recurrence	82
MARKET VALUE 2000-2020.....	83
CONTRALATERAL ACUTE LIMB ISCHEMIA	84
Occurrence of Contralateral PAD.....	84
Data on Contralateral ALI	85
NUMBER OF ALI CASES BY PRIMARY CAUSE—THROMBOSIS AND	
EMBOLISM	85
ALI Caused by Thrombosis—2000-2020.....	86
ALI Caused by Embolism—2000-2020	86
ALI PATIENTS IN EACH CLINICAL CLASSIFICATION.....	87
Percentage of Patients in Each SVS-ISCVS Classification.....	87
Number in Each SVS-ISCVS Classification 2004	88
Number of ALI Patients in Each Clinical Classification—2000-2020.....	88
RECOMMENDED INITIAL THERAPY BY CLINICAL CLASSIFICATION	89
PRIMARY MARKET POTENTIAL BY CLINICAL CLASSIFICATION.....	90
Definitions.....	90
Primary Market Potential Based on Current Recommended Initial Therapy—2005 ...	91
CLINICAL CATEGORY III	92
Percentage of Early and Late Presentation Forecast to Change	92
THROMBOLYTIC THERAPY	93
Primary Market Potential for Currently Approved Thrombolytics	93
Primary Market for Isolated Thrombolysis Devices.....	94
Primary Market for Devices to Speed Clot Dissolution	94
Primary Market for New Safer Thrombolytics.....	94
Primary Market for Microbubbles	95
PMT THERAPY.....	95
Primary Market Potential for Percutaneous Mechanical Thrombectomy.....	95
Primary Market for New Endovascular Devices	96

GP IIb/IIIa INHIBITORS	98
Primary Market Potential for GP IIb/IIIa Therapy	98
THROMBOEMBOLECTOMY	99
Primary Market Potential for Surgical Thromboembolectomy	99
REFERENCES	100
INDEX OF TABLES AND FIGURES.....	120
LIST OF COMPANIES	122
DISCLOSURE STATEMENT	124
CONTACT INFORMATION.....	125